Semaglutide vs Tirzepatide vs Retatrutide: Comparing GLP-1 Agonists

GLP-1 receptor agonists are among the most actively researched peptide classes in modern pharmacology. Semaglutide, tirzepatide, and retatrutide represent three generations of incretin-based compounds — each building on the previous with additional receptor targets and expanded pharmacological profiles. This article compares their mechanisms, published research, and key differences for researchers working in metabolic science.

Quick Comparison

Property	Semaglutide	Tirzepatide	Retatrutide
Receptor targets	GLP-1R	GLP-1R + GIP-R	GLP-1R + GIP-R + GCGR
Classification	Single agonist	Dual agonist	Triple agonist
Developer	Novo Nordisk	Eli Lilly	Eli Lilly
Administration	Weekly	Weekly	Weekly
Molecular basis	GLP-1 analogue	GIP-based backbone	Glucagon-based backbone
Key trials	STEP, SUSTAIN, SELECT	SURMOUNT, SURPASS	Phase 2 (Jastreboff 2023)

Semaglutide: The GLP-1 Receptor Agonist

Semaglutide is a GLP-1 receptor agonist developed by Novo Nordisk. It’s a modified GLP-1 analogue with amino acid substitutions and a C-18 fatty acid side chain that extends its half-life to approximately 7 days, enabling once-weekly administration.

Mechanism

Semaglutide activates the GLP-1 receptor, which is expressed on pancreatic beta cells, the central nervous system (hypothalamus and brainstem), the gastrointestinal tract, and cardiovascular tissue. GLP-1R activation produces multiple downstream effects:

• Glucose-dependent insulin secretion (pancreatic beta cells)
• Suppression of glucagon secretion (pancreatic alpha cells)
• Delayed gastric emptying
• Central appetite suppression via hypothalamic and brainstem circuits

Published Research

Semaglutide has the most extensive clinical trial program of any GLP-1 agonist:

• STEP trials: The STEP 1 trial (Wilding et al., NEJM, 2021) demonstrated significant weight reduction in participants with obesity over 68 weeks.
• SELECT trial: A cardiovascular outcomes trial (Lincoff et al., NEJM, 2023) showed a 20% reduction in major adverse cardiovascular events (MACE) in participants with overweight/obesity and established cardiovascular disease.
• SUSTAIN program: Multiple trials evaluating glucose-lowering efficacy in type 2 diabetes research.

Tirzepatide: The Dual GLP-1/GIP Agonist

Tirzepatide, developed by Eli Lilly, is the first dual GIP and GLP-1 receptor agonist. Built on a GIP backbone rather than GLP-1, it activates both incretin receptor pathways simultaneously.

Mechanism

Tirzepatide’s dual agonism targets two distinct but complementary pathways:

• GLP-1 receptor: Same effects as semaglutide — insulin secretion, glucagon suppression, gastric slowing, central appetite regulation.
• GIP receptor: GIP (glucose-dependent insulinotropic polypeptide) receptor activation enhances insulin secretion through an independent pathway and may have distinct effects on adipose tissue metabolism and lipid handling.

The addition of GIP receptor agonism appears to amplify metabolic effects beyond what GLP-1 agonism alone achieves. The exact mechanism of this amplification is an active area of investigation.

Published Research

• SURMOUNT-1: (Jastreboff et al., NEJM, 2022) demonstrated weight reduction of up to 22.5% at the highest dose over 72 weeks — surpassing results from single GLP-1 agonist trials.
• SURPASS program: Multiple trials in type 2 diabetes showing superior HbA1c reduction compared to existing GLP-1 agonists.
• SURMOUNT-MMO: Ongoing cardiovascular outcomes trial evaluating MACE reduction (results expected 2027).

Retatrutide: The Triple Agonist

Retatrutide (LY3437943), also developed by Eli Lilly, adds a third receptor target to the dual agonist approach: the glucagon receptor (GCGR). This makes it the first “triple agonist” — simultaneously activating GLP-1, GIP, and glucagon receptors.

Mechanism

Retatrutide combines the effects of both incretin pathways with direct glucagon receptor activation:

• GLP-1 + GIP: Same dual incretin effects as tirzepatide.
• Glucagon receptor: Glucagon agonism increases energy expenditure, hepatic lipid oxidation, and thermogenesis. While glucagon traditionally raises blood glucose, the concurrent GLP-1 and GIP agonism counterbalances this effect, maintaining glycemic control while adding the metabolic benefits of glucagon signaling.

The theoretical advantage of triple agonism is that it addresses metabolic dysfunction through three independent pathways simultaneously — appetite (GLP-1), nutrient handling (GIP), and energy expenditure (glucagon).

Published Research

• Phase 2 trial: (Jastreboff et al., NEJM, 2023) demonstrated weight reduction of up to 24.2% at 48 weeks — with the suggestion that the curve had not yet plateaued, meaning longer treatment could yield greater effects.
• Liver fat reduction: Post-hoc analyses showed dramatic reductions in hepatic fat content, relevant to MASLD/MASH research.
• Phase 3: Multiple Phase 3 trials currently enrolling (TRIUMPH program).

Comparing the Evidence

Outcome	Semaglutide	Tirzepatide	Retatrutide
Weight reduction (max published)	~16% (STEP 1)	~22.5% (SURMOUNT-1)	~24.2% (Phase 2)
CV outcomes data	✅ SELECT (20% MACE reduction)	⏳ SURMOUNT-MMO (pending)	❌ Not yet studied
Evidence maturity	Phase 3 + post-market	Phase 3	Phase 2 only
Liver fat data	Modest reduction	Significant reduction	Dramatic reduction
GI tolerability	Nausea common at initiation	Similar to semaglutide	Similar, dose-dependent

The Evolution of Incretin Research

These three compounds represent a clear trajectory in metabolic peptide research:

1. Single agonism (Semaglutide): Proved that targeting a single incretin receptor could produce meaningful metabolic effects. Established the therapeutic category with the most extensive safety and efficacy database.
2. Dual agonism (Tirzepatide): Demonstrated that adding a second receptor target (GIP) amplifies the metabolic response beyond what GLP-1 alone achieves. Raised the bar for efficacy.
3. Triple agonism (Retatrutide): Explores whether adding glucagon receptor activation — with its energy expenditure and hepatic lipid effects — further improves metabolic outcomes. Still in earlier-stage investigation.

Each step adds pharmacological complexity and potential efficacy, but also introduces new questions about long-term safety, optimal dosing, and the interplay between receptor pathways.

Research Considerations

For researchers designing studies involving GLP-1 agonists, several factors inform compound selection:

• Evidence maturity: Semaglutide has the deepest published evidence base, making it the most appropriate choice when aligning with established literature.
• Receptor specificity: Single (GLP-1), dual (GLP-1/GIP), or triple (GLP-1/GIP/GCGR) agonism depending on the pathways relevant to the research question.
• Metabolic endpoints: Tirzepatide and retatrutide show stronger hepatic fat reduction signals, relevant for MASLD/MASH research models.
• Cardiovascular context: Only semaglutide has completed cardiovascular outcomes trials to date.

References

1. Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002. PubMed
2. Lincoff AM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221-2232. PubMed
3. Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(4):327-340. PubMed
4. Jastreboff AM, et al. Triple-hormone-receptor agonist retatrutide for obesity. N Engl J Med. 2023;389(6):514-526. PubMed
5. Frías JP, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021;385(6):503-515. PubMed